.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Baxter
US Department of Justice
Covington
Julphar
Moodys
AstraZeneca
US Army
Express Scripts
Federal Trade Commission

Generated: June 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202078

« Back to Dashboard
NDA 202078 describes ZOLMITRIPTAN, which is a drug marketed by Aurobindo Pharma Ltd, Alembic Pharms Ltd, Macleods Pharms Ltd, Ajanta Pharma Ltd, Jubilant Generics, Glenmark Generics, Teva Pharms Usa, Pld Acquisitions Llc, Apotex Inc, Sun Pharma Global, Invagen Pharms, Mylan Pharms Inc, and Zydus Pharms Usa Inc, and is included in eighteen NDAs. It is available from fifteen suppliers. Additional details are available on the ZOLMITRIPTAN profile page.

The generic ingredient in ZOLMITRIPTAN is zolmitriptan. There are twenty drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.

Summary for NDA: 202078

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 202078

Suppliers and Packaging for NDA: 202078

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOLMITRIPTAN
zolmitriptan
TABLET;ORAL 202078 ANDA Apotex Corp 60505-3693 60505-3693-0 1 BLISTER PACK in 1 CARTON (60505-3693-0) > 6 TABLET, FILM COATED in 1 BLISTER PACK
ZOLMITRIPTAN
zolmitriptan
TABLET;ORAL 202078 ANDA Apotex Corp 60505-3694 60505-3694-0 1 BLISTER PACK in 1 CARTON (60505-3694-0) > 3 TABLET, FILM COATED in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2.5MG
Approval Date:May 14, 2013TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength5MG
Approval Date:May 14, 2013TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Covington
US Army
Harvard Business School
Queensland Health
Colorcon
QuintilesIMS
Chinese Patent Office
US Department of Justice
Merck
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot